<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02401477</url>
  </required_header>
  <id_info>
    <org_study_id>DUMC-LYJ-ILA01</org_study_id>
    <nct_id>NCT02401477</nct_id>
  </id_info>
  <brief_title>Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection</brief_title>
  <official_title>Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection; Studies From Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Il-Yang Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Il-Yang Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assessed eradication rate of dual therapy with high doses of Ilaprazole 40mg BID
      and Amoxicillin 750mg QID for 14 days on Helicobacter pylori infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study performed to assess the eradication rate of H.pylori after 14 days treatment. The
      treatment is defined as those participants who confirmed on gastric or duodenal ulcer
      (including scar stage) or gastritis by endoscopy or the participants who received endoscopic
      treamtment for gastric polyp, gastric adenocarcinoma, confirmed to be H.pylori positive
      patients by the Biopsy or CLO test or Serological Diagnosis.

      Patients administered Ilaprazole 40mg BID and Amoxicillin 750mg QID for 14days. The
      eradication rate on High dose dual therapy assessed by UBT test at Day 49±7.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The eradication rate of H.pylori</measure>
    <time_frame>Day 49±7</time_frame>
    <description>The eradication rate of H.pylori after 14 days treatment is defined as those participants who confirmed on gastric or duodenal ulcer (including scar stage) or gastritis by endoscopy or the participants who received endoscopic treatment for gastric polyp, gastric adenocarcinoma, confirmed to be H.pylori positive patients by the Biopsy or CLO test or Serological Diagnosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of patients with Adverse Events</measure>
    <time_frame>Day 49±7</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Helicobacter Infections</condition>
  <arm_group>
    <arm_group_label>Ilaprazole + Amoxicillin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Noltec(Ilaprazole) 10mg 4 tablets BID + Ildong-Amoxicillin 500mg 1capsule and 250mg 1capsule QID by oral for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ilaprazole + Amoxicillin</intervention_name>
    <description>Ilaprazole 40mg BID, dosage form : delayed release tablet Amoxicillin 750mg QID, dosage form : capsule</description>
    <arm_group_label>Ilaprazole + Amoxicillin</arm_group_label>
    <other_name>Ilaprazole</other_name>
    <other_name>Amoxicillin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject who is confirmed on gastric or duodenal ulcer (including scar stage) by
             endoscopy or among the participants who received endoscopic treamtment for gastric
             polyp, gastric adenocarcinoma, confirmed to be H.pylori positive patients by the
             Biopsy, CLO test and Serological Diagnosis.

          -  Subject who fully understands conditions of clinical trial.

          -  Subject who agrees to participate and spontaneously sign the ICF

        Exclusion Criteria:

          -  Known hypersensitivity to any component of Ilaprazole, Amoxicillin(Penicillin
             Antibiotics).

          -  Subjects who are taking contraindicated medications for experimental and concomitant
             drug.

          -  Administrated of PPI, antibiotic medication within 4 weeks prior to commencement of
             the study.

          -  Pregnant and/or lactating women

          -  Reproductive aged women not using contraception

          -  Uncontrolled diabetics

          -  Uncontrolled hypertension

          -  Uncontrolled liver dysfunction

          -  Uncontrolled kidney dysfunction

          -  Alcoholics

          -  Subjects with a history or possibility of digestive malignancy within 5 years

          -  Subjects with a history of gastrectomy or esophagectomy

          -  Subjects with hereditary diseases such as Galactose intolerance, Lapp lactose
             deficiency, glucose-galactose malabsorption.

          -  Infectious mononucleosis patients

          -  Subjects participating in a clinical trial before another trial wihin 30 days

          -  Inconsistence judged subject by researcher
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YoonJeong Lim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DongGuk University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dongguk University Ilsan Hospital</name>
      <address>
        <city>Goyang-si, Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2015</study_first_submitted>
  <study_first_submitted_qc>March 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <last_update_submitted>November 2, 2015</last_update_submitted>
  <last_update_submitted_qc>November 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>helicobacter pylori</keyword>
  <keyword>ilaprazole</keyword>
  <keyword>eradication</keyword>
  <keyword>dual therapy</keyword>
  <keyword>high dose therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

